Michael Carnahan, MD
Family Medicine · Ardmore, OKNPI 1871607903
Payments from drug & device makers
Across 343 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$616
- AbbVie$574
- AstraZeneca$435
- Astellas Pharma US Inc$387
- Sanofi-aventis U.S. LLC$379
- Amgen$354
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,83697%
- Education$1343%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 58 | $616 |
| AbbVie(2 entities) | 39 | $574 |
| AstraZeneca | 27 | $435 |
| Astellas Pharma US Inc | 14 | $387 |
| Sanofi-aventis U.S. LLC | 25 | $379 |
| Amgen | 24 | $354 |
| Novo Nordisk | 22 | $353 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $328 |
| Lilly USA, LLC | 30 | $307 |
| Boehringer Ingelheim | 18 | $267 |
| Johnson & Johnson | 9 | $156 |
| Bayer | 9 | $132 |
| Sunovion Pharmaceuticals Inc. | 9 | $73 |
| Merck | 5 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| Amarin Pharma, Inc. | 4 | $57 |
| Pfizer | 4 | $53 |
| Ironwood Pharmaceuticals, Inc | 3 | $45 |
| Boston Scientific | 1 | $44 |
| Corium, LLC | 2 | $44 |
| Biogen | 3 | $43 |
| Genentech USA, Inc. | 3 | $41 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $12 |
| Organon | 1 | $8 |
How this compares
$4,970 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 150 | $155,830 |
| EliquisApixaban | 115 | $110,121 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $58,457 |
| OzempicSemaglutide | 63 | $57,573 |
| XareltoRivaroxaban | 26 | $36,930 |
| MounjaroTirzepatide | 33 | $36,918 |
| JardianceEmpagliflozin | 31 | $36,306 |
| TrulicityDulaglutide | 19 | $29,540 |
| JanuviaSitagliptin Phosphate | 26 | $27,116 |
| LinzessLinaclotide | 29 | $24,790 |
| ViberziEluxadoline | 14 | $21,161 |
| KerendiaFinerenone | 24 | $20,646 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $20,315 |
| MyrbetriqMirabegron | 29 | $19,604 |
| ProliaDenosumab | 12 | $18,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $435 | $170,130174 claims |
| PfizerEliquis | $53 | $110,121115 claims |
| Lilly USA, LLCMounjaro, Trulicity | $307 | $66,45752 claims |
| GSKTrelegy Ellipta | $616 | $58,45784 claims |
| Novo NordiskOzempic | $353 | $57,57363 claims |
| Johnson & JohnsonXarelto, Invokana | $156 | $49,67742 claims |
| AbbVieLinzess, Viberzi | $574 | $45,95143 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $267 | $44,05746 claims |
| MerckJanuvia, Janumet | $66 | $41,05043 claims |
| BayerKerendia | $132 | $20,64624 claims |
| Astellas Pharma US IncMyrbetriq | $387 | $19,60429 claims |
| AmgenProlia | $354 | $18,41512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Ardmore
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.